Floatz logo

Prax-628

Focal Onset Seizure

Praxis Precision MedicinesPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Focal Onset Seizure cohort.

Asset / SponsorPhaseRating
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A

View all 50 →

Same molecule, other indications

Prax-628 is also rated in:

generalized epilepsyDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →